David Weaver, CEO of Aphex™ BioCleanse Systems, Inc. discusses the world’s first proprietary non-alcohol, non-toxic, and hydrogen-based cleaning technology. The technology, called Hy-IQ® Water, has a unique method of action that uses hydrogen ions traveling at nearly the speed of light to breach the cell walls of exoskeleton germs. The company has filed to be the first FDA cleared non-alcohol hand sanitizer. Aphex has created other products that are safe for pets, can be used on vegetables and fruits, and in industrial and clinical settings.
Sarah Cross, Ph.D., Associate Scientific Director, Women’s Health, U.S. Medical Affairs at AbbVie discusses the newly formed Alliance for Endometriosis by seven women’s health-focused organizations – AbbVie, the American College of Obstetricians and Gynecologists, Black Women’s Health Imperative, the Endometriosis Association, GE Healthcare, Healthy Women and the International Pelvic Pain Society. The goal of the alliance is to improve the lives of the one in 10 women of reproductive age living with endometriosis in the United States. The Alliance is actively seeking insights via a survey at AllianceForEndo.com and encouraging the endometriosis community to share their experiences to better understand their wants and needs.
Dr. Douglas Rex, MD., Distinguished Professor Emeritus at Indiana University School of Medicine, discusses the recent (Nov 2020) U.S. FDA approval of Sebela Pharmaceuticals’ SUTAB® Tablets (sodium sulfate, magnesium sulfate, and potassium chloride), a new, safe, and effective alternative to liquid colonoscopy prep solution. He worked as a lead principal investigator for the Phase 3 clinical trials of SUTAB
Lead researcher, Dr. David Vossler, MD, FAAN FACNS FAES, Department of Neurology, University of Washington, discusses the recent U.S. FDA approval of UCB’s VIMPAT® (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older and VIMPAT injection for intravenous use in children four years of age and older.
Returning guest, Dr. Adriana Carrillo-Iregui, pediatric endocrinologist within the Division of Pediatric Endocrinology at Nicklaus Children’s Hospital discusses immunotherapy for at risk children that is an emerging treatment for Type 1 diabetes. She explains how it works and which pediatric patients are candidates for this drug.
Dr. Amy Shapiro, hematologist-oncologist and CEO and co-medical director at the Indiana Hemophilia & Thrombosis Center, Inc., discusses important treatment developments that have brought hope to people living with hemophilia A. She is joined by Guy who is living with hemophilia A.
Dr. Jessica Whelan, family psychiatric nurse practitioner discusses why the holiday season can be particularly challenging for people living with mental health conditions like bipolar I disorder, the difference between holiday blues and bipolar I disorder, and a treatment option people living with bipolar I disorder can discuss with their doctors. Visit www.vraylar.com to learn more including additional safety information.
Returning guest, board-certified internist, Dr. Jacob Teitelbaum discusses a recent study published in the “American Journal of Clinical Pathology” (Nov 2020) that showed that 59 percent of patients with COVID-19 are vitamin D-deficient when they’re admitted; and the deficiency was most pronounced in men with advanced stages of COVID-related pneumonia. He also talks about the long term effects of COVID-19, known as “long-hauler syndrome” and his clinical work and research on post-viral energy depletion.
Paul Hastings, CEO of Nkarta Therapeutics discusses results from their NKX101 study, an allogeneic CAR Natural Killer (NK) cell therapy, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS).
Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading U.S. medical affairs across asthma and COPD, discusses a recent (Dec 2020) study funded by GSK and co-developed by GSK and CHEST as part of the CHEST “Clinical Perspectives” series evaluating the role of pulmonologists, COPD exacerbations, and the need to improve COPD management and education.